{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:08:55Z","timestamp":1780337335432,"version":"3.54.1"},"reference-count":119,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Antibody-drug conjugates (ADCs) are designed to deliver potent cytotoxic agents into tumor tissues. During the last two decades, a plethora of ADCs have been successfully developed and used for several indications, including hematologic and solid tumors. In this work, we systematically reviewed the progress in ADC development for the treatment of HNC. Methods: This review was registered in PROSPERO database. A comprehensive search was conducted following PRISMA guidelines and using PubMed, Scopus and Web of Science database. Results: In total, 19 studies were included. Due to the significant heterogeneity of the outcome measures, meta-analysis was not performed, and data were summarized in tables. HNC results are poorly represented in the cohorts of completed clinical trials; published data are mostly focused on safety evaluation rather than efficacy of ADCs. Conclusions: Although several novel agents against a wide range of different antigens were investigated, showing promising results at a preclinical level, most of the targets reported in this review are not specific for HNC; hence, the development of ADCs tailored for the HNC phenotype could open up new therapeutic perspectives. Moreover, the results from the present systematic review call attention to how limited is the application of current clinical trials in HNC.<\/jats:p>","DOI":"10.3390\/cancers13133126","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T22:10:59Z","timestamp":1624399859000},"page":"3126","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: A Systematic Review"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7652-1660","authenticated-orcid":false,"given":"Vittoria","family":"Perrotti","sequence":"first","affiliation":[{"name":"Department of Medical, Oral and Biotechnological Sciences, Gabriele d\u2019Annunzio University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5080-5921","authenticated-orcid":false,"given":"Vito Carlo Alberto","family":"Caponio","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Foggia, 71100 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7304-3752","authenticated-orcid":false,"given":"Marco","family":"Mascitti","sequence":"additional","affiliation":[{"name":"Department of Clinical Specialistic and Dental Sciences, Marche Polytechnic University, 60121 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4633-4893","authenticated-orcid":false,"given":"Lorenzo","family":"Lo Muzio","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Foggia, 71100 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Piattelli","sequence":"additional","affiliation":[{"name":"Department of Medical, Oral and Biotechnological Sciences, Gabriele d\u2019Annunzio University of Chieti-Pescara, 66100 Chieti, Italy"},{"name":"Fondazione Villa Serena per la Ricerca, Citt\u00e0 S. Angelo, 65121 Pescara, Italy"},{"name":"Casa di Cura Villa Serena, Citt\u00e0 S. Angelo, 65121 Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Rubini","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Public Health, Marche Polytechnic University, 60121 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6719-2535","authenticated-orcid":false,"given":"Emily","family":"Capone","sequence":"additional","affiliation":[{"name":"Department of Innovative Technologies in Medicine & Dentistry, University of Chieti-Pescara, 66100 Chieti, Italy"},{"name":"Center for Advanced Studies and Technology (CAST), Via Polacchi 11, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4494-915X","authenticated-orcid":false,"given":"Gianluca","family":"Sala","sequence":"additional","affiliation":[{"name":"Department of Innovative Technologies in Medicine & Dentistry, University of Chieti-Pescara, 66100 Chieti, Italy"},{"name":"Center for Advanced Studies and Technology (CAST), Via Polacchi 11, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"ref_1","first-page":"1","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.coms.2014.01.001","article-title":"Epidemiologic Trends in Head and Neck Cancer and Aids in Diagnosis","volume":"26","author":"Vigneswaran","year":"2014","journal-title":"Oral Maxillofac. Surg. Clin. North Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1080\/0284186X.2016.1185148","article-title":"Trends in all-cause five-year mortality after head and neck cancers diagnosed over a period of 33 years. Focus on estimated degree of association with human papillomavirus","volume":"55","author":"Svahn","year":"2016","journal-title":"Acta Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1002\/cncr.23521","article-title":"Targeted therapy in head and neck cancer: State of the art 2007 and review of clinical applications","volume":"112","author":"Langer","year":"2008","journal-title":"Cancer"},{"key":"ref_5","unstructured":"(2021, May 16). Institute NC Cancer Stat Facts: Oral Cavity and Pharynx Cancer, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/oralcav.html."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.2010-S3-03","article-title":"Induction Chemotherapy for Head and Neck Cancer: Recent Data","volume":"15","author":"Vokes","year":"2010","journal-title":"Oncologist"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11864-011-0176-y","article-title":"Current Treatment Options for Metastatic Head and Neck Cancer","volume":"13","author":"Price","year":"2012","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.critrevonc.2005.06.002","article-title":"Epidermal growth factor receptor directed therapy in head and neck cancer","volume":"57","author":"Choong","year":"2006","journal-title":"Crit. Rev. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00001622-200205000-00014","article-title":"Novel therapeutics for head and neck cancer","volume":"14","author":"Kim","year":"2002","journal-title":"Curr. Opin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/14737140.2020.1708197","article-title":"Palliative chemotherapy in head and neck cancer: Balancing between beneficial and adverse effects","volume":"20","author":"Rajendra","year":"2020","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_12","first-page":"3314","article-title":"Strategies for enzyme\/prodrug cancer therapy","volume":"7","author":"Xu","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Vaddepally, R.K., Kharel, P., Pandey, R., Garje, R., and Chandra, A.B. (2020). Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers, 12.","DOI":"10.3390\/cancers12030738"},{"key":"ref_14","first-page":"871","article-title":"Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck","volume":"3","author":"Merlano","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1200\/JCO.2005.04.8306","article-title":"Epidermal Growth Factor Receptor Biology in Head and Neck Cancer","volume":"24","author":"Kalyankrishna","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/jjco\/hyt030","article-title":"Phase II Study of Cetuximab Plus Concomitant Boost Radiotherapy in Japanese Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck","volume":"43","author":"Okano","year":"2013","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/jjco\/hyt034","article-title":"Platinum-based Chemotherapy Plus Cetuximab for the First-line Treatment of Japanese Patients with Recurrent and\/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of a Phase II Trial","volume":"43","author":"Yoshino","year":"2013","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1158\/0008-5472.CAN-16-0754","article-title":"Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism","volume":"77","author":"Braig","year":"2016","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1002\/cncr.32929","article-title":"A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent\/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study","volume":"126","author":"Seiwert","year":"2020","journal-title":"Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1158\/1078-0432.CCR-17-1261","article-title":"Head and Neck Carcinoma Immunotherapy: Facts and Hopes","volume":"24","author":"Whiteside","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.oraloncology.2014.08.005","article-title":"Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: A systematic review and meta-analysis of published studies","volume":"50","author":"Petrelli","year":"2014","journal-title":"Oral Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41368-020-0084-8","article-title":"Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma","volume":"12","author":"Mei","year":"2020","journal-title":"Int. J. Oral Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","article-title":"Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522","volume":"32","author":"Ang","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_27","first-page":"105","article-title":"Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas","volume":"11","author":"William","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-Drug Conjugate-Based Therapeutics: State of the Science","volume":"111","author":"Birrer","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1158\/1078-0432.CCR-19-0272","article-title":"Antibody\u2013Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index","volume":"25","author":"Coats","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40264-018-0775-7","article-title":"Safety and Tolerability of Antibody-Drug Conjugates in Cancer","volume":"42","author":"Robak","year":"2019","journal-title":"Drug Saf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1051\/medsci\/200925121046","article-title":"Les immunoconjugu\u00e9s, anticorps \u00abarm\u00e9s\u00bb pour combattre le cancer","volume":"25","author":"Haeuw","year":"2009","journal-title":"M\u00e9decine\/Sciences"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Joubert, N., Beck, A., Dumontet, C., and Denevault-Sabourin, C. (2020). Antibody\u2013Drug Conjugates: The Last Decade. Pharmaceuticals, 13.","DOI":"10.3390\/ph13090245"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2165\/00003495-200161090-00007","article-title":"Gemtuzumab ozogamicin","volume":"61","author":"McGavin","year":"2001","journal-title":"Drugs"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/bcp.12988","article-title":"Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment","volume":"82","author":"Zhao","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s40265-017-0802-5","article-title":"Inotuzumab Ozogamicin: First Global Approval","volume":"77","author":"Lamb","year":"2017","journal-title":"Drugs"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-00369-0","article-title":"Single-agent belantamab mafodotin for relapsed\/refractory multiple myeloma: Analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study","volume":"10","author":"Richardson","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/14712598.2019.1614558","article-title":"Moxetumomab pasudotox for the treatment of hairy cell leukemia","volume":"19","author":"Janus","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-014-0201-0","article-title":"Trastuzumab Emtansine: A Review of Its Use in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab-Based Therapy","volume":"74","author":"Dhillon","year":"2014","journal-title":"Drugs"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1\/Programmed Death Ligand 1 Therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1860476","DOI":"10.1080\/19420862.2020.1860476","article-title":"Antibodies to watch in 2021","volume":"13","author":"Kaplon","year":"2021","journal-title":"mAbs"},{"key":"ref_45","first-page":"50","article-title":"Evidence-based decision making in dental hygiene education, practice, and research","volume":"75","author":"Forrest","year":"2001","journal-title":"J. Dent. Hyg."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int. J. Surg."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Hooijmans, C.R., Rovers, M.M., De Vries, R.B.M., Leenaars, M., Ritskes-Hoitinga, M., and Langendam, M.W. (2014). SYRCLE\u2019s risk of bias tool for animal studies. BMC Med Res. Methodol., 14.","DOI":"10.1186\/1471-2288-14-43"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1200\/JCO.18.01100","article-title":"RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis","volume":"37","author":"Isaac","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2147\/CLEP.S66677","article-title":"Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: The Newcastle\u2013Ottawa Scale and the RTI item bank","volume":"6","author":"Margulis","year":"2014","journal-title":"Clin. Epidemiol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Gagnier, J.J., Moher, D., Boon, H., Beyene, J., and Bombardier, C. (2012). Investigating clinical heterogeneity in systematic reviews: A methodologic review of guidance in the literature. BMC Med Res. Methodol., 12.","DOI":"10.1186\/1471-2288-12-111"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1158\/1535-7163.MCT-20-0149","article-title":"Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody\u2013Drug Conjugate","volume":"19","author":"Anderson","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/1535-7163.MCT-11-0725","article-title":"A Human Fab-Based Immunoconjugate Specific for the LMP1 Extracellular Domain Inhibits Nasopharyngeal Carcinoma Growth In Vitro and In Vivo","volume":"11","author":"Chen","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s10637-020-00908-3","article-title":"A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR","volume":"38","author":"Cleary","year":"2020","journal-title":"Investig. New Drugs"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): A first-in-human, multicentre, phase 1\u20132 trial","volume":"20","author":"Concin","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/1568009617666170427105417","article-title":"Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate","volume":"19","author":"Ghanemi","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/1878-0261.12600","article-title":"TR1801-ADC: A highly potent cMet antibody\u2013drug conjugate with high activity in patient-derived xenograft models of solid tumors","volume":"14","author":"Gymnopoulos","year":"2019","journal-title":"Mol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/1061186031000121478","article-title":"Targeting of Human Squamous Carcinomas by SPA470-doxorubicin Immunoconjugates","volume":"11","author":"Hebert","year":"2003","journal-title":"J. Drug Target."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/1078-0432.CCR-16-1834","article-title":"5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma","volume":"23","author":"Kerk","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1158\/1078-0432.CCR-07-5211","article-title":"Effective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor Fibroblasts","volume":"14","author":"Ostermann","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1158\/0008-5472.CAN-18-0327","article-title":"LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody\u2013Drug Conjugates","volume":"78","author":"Purcell","year":"2018","journal-title":"Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.oraloncology.2007.10.009","article-title":"Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma","volume":"44","author":"Riechelmann","year":"2008","journal-title":"Oral Oncol."},{"key":"ref_63","first-page":"927","article-title":"Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck","volume":"30","author":"Sauter","year":"2007","journal-title":"Int. J. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1158\/1535-7163.MCT-20-0116","article-title":"Preclinical Development of MGC018, a Duocarmycin-based Antibody\u2013drug Conjugate Targeting B7-H3 for Solid Cancer","volume":"19","author":"Scribner","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1158\/1535-7163.MCT-16-0431","article-title":"RN927C, a Site-Specific Trop-2 Antibody\u2013Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models","volume":"15","author":"Strop","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.oraloncology.2013.07.006","article-title":"A novel extracellular drug conjugate significantly inhibits head and neck squamous cell carcinoma","volume":"49","author":"Sweeny","year":"2013","journal-title":"Oral Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/1535-7163.MCT-18-0471","article-title":"Treating Tissue Factor\u2013Positive Cancers with Antibody\u2013Drug Conjugates That Do Not Affect Blood Clotting","volume":"17","author":"Theunissen","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","article-title":"Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors","volume":"10","author":"Tsurutani","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"33446","DOI":"10.18632\/oncotarget.26002","article-title":"RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models","volume":"9","author":"Wong","year":"2018","journal-title":"Oncotarget"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbrc.2012.11.055","article-title":"Recombinant expression and purification of a tumor-targeted toxin in Bacillus anthracis","volume":"430","author":"Bachran","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Benedetto, R., Massicano, A.V.F., Silva, J.J., Boas, C.A.W.V., Mengatti, J., and De Araujo, E.B. (2018). Development of radioimmunoconjugate for diagnosis and management of head-and-neck subclinical cancer and colorectal carcinoma. Braz. J. Pharm. Sci., 53.","DOI":"10.1590\/s2175-97902017000417039"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/CJI.0000000000000263","article-title":"Generation of a Transgenic BALB\/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy","volume":"42","author":"Bera","year":"2019","journal-title":"J. Immunother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models","volume":"76","author":"Satpayev","year":"2016","journal-title":"Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.canlet.2005.07.035","article-title":"Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles","volume":"239","author":"Huang","year":"2006","journal-title":"Cancer Lett."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"24457","DOI":"10.18632\/oncotarget.14904","article-title":"Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes","volume":"8","author":"Jang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1158\/1078-0432.CCR-04-0314","article-title":"Nitric Oxide Accelerates Interleukin-13 Cytotoxin-Mediated Regression in Head and Neck Cancer Animal Model","volume":"10","author":"Kawakami","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"28164","DOI":"10.18632\/oncotarget.4461","article-title":"Functional Genomic mRNA Profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types","volume":"6","author":"Lamberts","year":"2015","journal-title":"Oncotarget"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1600-0714.2009.00759.x","article-title":"Targeted drug delivery system for oral cancer therapy using sonoporation","volume":"38","author":"Maeda","year":"2009","journal-title":"J. Oral Pathol. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jconrel.2018.08.005","article-title":"P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors","volume":"286","author":"Mao","year":"2018","journal-title":"J. Control Release"},{"key":"ref_80","first-page":"263","article-title":"Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR","volume":"26","author":"Munasinghe","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1158\/1541-7786.MCR-17-0333","article-title":"Syngeneic Mouse Models of Oral Cancer Are Effectively Targeted by Anti\u2013CD44-Based NIR-PIT","volume":"15","author":"Nagaya","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_82","first-page":"593","article-title":"Improved Tumor-to-Organ Ratios of a Novel 67Ga-Human Epidermal Growth Factor Radionuclide Conjugate with Preadministered Antiepidermal Growth Factor Receptor Affibody Molecules","volume":"26","author":"Sandstrom","year":"2011","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/1066896920978597","article-title":"TROP-2, 5hmC, and IDH1 Expression in Anaplastic Thyroid Carcinoma","volume":"29","author":"Seok","year":"2021","journal-title":"Int. J. Surg. Pathol."},{"key":"ref_84","first-page":"281","article-title":"Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models","volume":"8","author":"Strome","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/odi.13203","article-title":"Smart cell-specific protein therapeutics for head and neck cancer","volume":"26","year":"2020","journal-title":"Oral Dis."},{"key":"ref_86","first-page":"2809","article-title":"A novel anti-EGFR monoclonal antibody (EMab-17) exerts antitumor activity against oral squamous cell carcinomas via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity","volume":"19","author":"Takei","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2016.03.014","article-title":"EGFR targeted nanobody\u2013photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer","volume":"229","author":"Boonstra","year":"2016","journal-title":"J. Control Release"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1600-0722.2004.00157.x","article-title":"Delivery of cytolethal distending toxin B induces cell cycle arrest and apoptosis in gingival squamous cell carcinoma in vitro","volume":"112","author":"Yamamoto","year":"2004","journal-title":"Eur. J. Oral Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.3892\/ol.2013.1219","article-title":"Characterization of human Fab antibody fragments specific to LMP1 (HLEAFab) in nasopharyngeal carcinoma for potential molecular diagnosis and therapeutic applications","volume":"5","author":"Zhang","year":"2013","journal-title":"Oncol. Lett."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/abbs\/gmy046","article-title":"Photothermal treatment with EGFRmAb\u2013AuNPs induces apoptosis in hypopharyngeal carcinoma cells via PI3K\/AKT\/mTOR and DNA damage response pathways","volume":"50","author":"Zhang","year":"2018","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_91","first-page":"7350","article-title":"Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma","volume":"62","author":"Ang","year":"2002","journal-title":"Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"19024","DOI":"10.1073\/pnas.1111963108","article-title":"Genomic dissection of the epidermal growth factor receptor (EGFR)\/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers","volume":"108","author":"Morris","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1158\/0008-5472.CAN-08-2881","article-title":"The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma","volume":"69","author":"Seiwert","year":"2009","journal-title":"Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/982879","article-title":"Receptor-Tyrosine-Kinase-Targeted Therapies for Head and Neck Cancer","volume":"2011","author":"Elferink","year":"2011","journal-title":"J. Signal Transduct."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1021\/acsmedchemlett.6b00062","article-title":"Design and Synthesis of Tesirine, a Clinical Antibody\u2013Drug Conjugate Pyrrolobenzodiazepine Dimer Payload","volume":"7","author":"Tiberghien","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Lucas, A.T., Price, L.S.L., Schorzman, A.N., Storrie, M., Piscitelli, J.A., Razo, J., and Zamboni, W.C. (2018). Factors Affecting the Pharmacology of Antibody\u2013Drug Conjugates. Antibodies, 7.","DOI":"10.3390\/antib7010010"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The Latest Research and Development into the Antibody\u2013Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem. Pharm. Bull."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3892\/ijo.2011.949","article-title":"Expression of B7-H3 in hypopharyngeal squamous cell carcinoma as a predictive indicator for tumor metastasis and prognosis","volume":"38","author":"Katayama","year":"2011","journal-title":"Int. J. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s12105-020-01222-3","article-title":"Evaluation Challenges in the Validation of B7-H3 as Oral Tongue Cancer Prognosticator","volume":"15","author":"Wirsing","year":"2021","journal-title":"Head Neck Pathol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Christensen, A., Kiss, K., Lelkaitis, G., Juhl, K., Persson, M., Charabi, B.W., Mortensen, J., Forman, J.L., S\u00f8rensen, A.L., and Jensen, D.H. (2017). Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): Tumor expression patterns and prognostic value in oral cancer. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3563-3"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1158\/0008-5472.CAN-10-3919","article-title":"Delineation of a Cellular Hierarchy in Lung Cancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells","volume":"71","author":"Damelin","year":"2011","journal-title":"Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1046\/j.1471-4159.2003.01537.x","article-title":"The immunoglobulin-superfamily molecule basigin is a binding protein for oligomannosidic carbohydrates: An anti-idiotypic approach","volume":"84","author":"Heller","year":"2003","journal-title":"J. Neurochem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/jop.13088","article-title":"CD147 promotes proliferation and migration of oral cancer cells by inhibiting junctions between E-cadherin and \u03b2-catenin","volume":"49","author":"Min","year":"2020","journal-title":"J. Oral Pathol. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yexmp.2017.01.002","article-title":"Inhibition of CD147 expression promotes chemosensitivity in HNSCC cells by deactivating MAPK\/ERK signaling pathway","volume":"102","author":"Ma","year":"2017","journal-title":"Exp. Mol. Pathol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Linz, C., Brands, R.C., Kertels, O., Dierks, A., Brumberg, J., Gerhard-Hartmann, E., Hartmann, S., Schirbel, A., Serfling, S., and Zhi, Y. (2021). Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity\u2014Initial experience and comparison to [18F]FDG PET\/CT and MRI. Eur. J. Nucl. Med. Mol. Imaging.","DOI":"10.1007\/s00259-021-05422-z"},{"key":"ref_106","first-page":"1977","article-title":"The production of the endostatin precursor collagen XVIII in head and neck carcinomas is modulated by CBP2\/Hsp47","volume":"22","author":"Ollins","year":"2002","journal-title":"Anticancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Chen, J., Zhou, J., Lu, J., Xiong, H., Shi, X., and Gong, L. (2014). Significance of CD44 expression in head and neck cancer: A systemic review and meta-analysis. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-15"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(08)60728-X","article-title":"Head and neck cancer","volume":"371","author":"Argiris","year":"2008","journal-title":"Lancet"},{"key":"ref_109","first-page":"2710","article-title":"Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer: Current Approaches and Future Considerations of Photothermal Therapies","volume":"10","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Network (2015). Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature, 517, 576\u2013582.","DOI":"10.1038\/nature14129"},{"key":"ref_111","first-page":"5519","article-title":"The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients","volume":"35","author":"Barak","year":"2015","journal-title":"Anticancer. Res."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Rabassa, M.E., Croce, M.V., Pereyra, A., and Segal-Eiras, A. (2006). MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): A multivariate analysis. BMC Cancer, 6.","DOI":"10.1186\/1471-2407-6-253"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1126\/science.1208130","article-title":"The Mutational Landscape of Head and Neck Squamous Cell Carcinoma","volume":"333","author":"Stransky","year":"2011","journal-title":"Science"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Von Witzleben, A., Wang, C., Laban, S., Savelyeva, N., and Ottensmeier, C.H. (2020). HNSCC: Tumour Antigens and Their Targeting by Immunotherapy. Cells, 9.","DOI":"10.3390\/cells9092103"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41199-020-00051-9","article-title":"An update on angiogenesis targeting in head and neck squamous cell carcinoma","volume":"5","author":"Micaily","year":"2020","journal-title":"Cancers Head Neck"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2015.08.068","article-title":"Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges","volume":"163","author":"Day","year":"2015","journal-title":"Cell"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.1200\/JCO.2018.36.15_suppl.6039","article-title":"RM-1929 photo-immunotherapy in patients with recurrent head and neck cancer: Results of a multicenter phase 2a open-label clinical trial","volume":"36","author":"Gillenwater","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"6014","DOI":"10.1200\/JCO.2019.37.15_suppl.6014","article-title":"Results of a phase 2a, multicenter, open-label, study of RM-1929 photoimmunotherapy (PIT) in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC)","volume":"37","author":"Cognetti","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/intimm\/dxaa037","article-title":"Near-infrared photoimmunotherapy of cancer: A new approach that kills cancer cells and enhances anti-cancer host immunity","volume":"33","author":"Kobayashi","year":"2021","journal-title":"Int. Immunol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/13\/3126\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:21:31Z","timestamp":1760163691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/13\/3126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":119,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["cancers13133126"],"URL":"https:\/\/doi.org\/10.3390\/cancers13133126","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]}}}